scholarly journals Local Treatment of Breast Cancer Liver Metastasis

Cancers ◽  
2019 ◽  
Vol 11 (9) ◽  
pp. 1341 ◽  
Author(s):  
Reto Bale ◽  
Daniel Putzer ◽  
Peter Schullian
Keyword(s):  
Breast Cancer ◽  
Radiofrequency Ablation ◽  
Liver Metastasis ◽  
Thermal Ablation ◽  
Treatment Options ◽  
Local Treatment ◽  
Complication Rates ◽  
Treatment Standard ◽  
Systemic Treatments ◽  
Breast Cancer Liver Metastasis

Breast cancer represents a leading cause of death worldwide. Despite the advances in systemic therapies, the prognosis for patients with breast cancer liver metastasis (BCLM) remains poor. Especially in case of failure or cessation of systemic treatments, surgical resection for BCLMs has been considered as the treatment standard despite a lack of robust evidence of benefit. However, due to the extent and location of disease and physical condition, the number of patients with BCLM who are eligible for surgery is limited. Palliative locoregional treatments of liver metastases (LM) include transarterial embolization (TAE), transarterial chemoembolization (TACE), and selective internal radiotherapy (SIRT). Percutaneous thermal ablation methods, such as radiofrequency ablation (RFA) and microwave ablation (MWA), are considered potentially curative local treatment options. They are less invasive, less expensive and have fewer contraindications and complication rates than surgery. Because conventional ultrasound- and computed tomography-guided single-probe thermal ablation is limited by tumor size, multi-probe stereotactic radiofrequency ablation (SRFA) with intraoperative image fusion for immediate, reliable judgment has been developed in order to treat large and multiple tumors within one session. This review focuses on the different minimally invasive local and locoregional treatment options for BCLM and attempts to describe their current and future role in the multidisciplinary treatment setting.

BRECLIM - a randomized clinical trial investigating local treatment for breast cancer liver metastasis

2020 ◽  
Vol 46 (2) ◽  
pp. e14
Author(s):  
Oskar Hemmingsson ◽  
Malin Sund ◽  
Helena Taflin ◽  
Marcus Sundén ◽  
Anne Andersson
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Liver Metastasis ◽  
Randomized Clinical Trial ◽  
Local Treatment ◽  
Breast Cancer Liver Metastasis

scholarly journals Evolving treatment strategies of brain metastases from breast cancer: current status and future direction

2020 ◽  
Vol 12 ◽  
pp. 175883592093611 ◽  
Author(s):  
Jae Sik Kim ◽  
In Ah Kim
Keyword(s):  
Breast Cancer ◽  
Treatment Options ◽  
Tumor Biology ◽  
Local Treatment ◽  
Treatment Strategies ◽  
Current Treatment ◽  
Current Status ◽  
Breast Cancer Patients ◽  
Antitumor Effects ◽  
Systemic Treatments

Remarkable progress in breast cancer treatment has improved patient survival, resulting in an increased incidence of brain metastasis (BM). Current treatment options for BM are limited and are generally used for palliative purposes. Historically, local treatment, consisting of radiotherapy and surgery, is the standard of care due to delivery limitations of systemic treatments through the blood–brain barrier. However, as novel biological mechanisms for tumors and BM have been discovered, several innovative systemic agents, such as small-molecular-targeted therapy and immunotherapy, have begun to change the treatment paradigm. In addition, efforts to maximize antitumor effects have been attempted using combination therapy, informed by tumor biology. In this comprehensive review, we will highlight various clinical trials investigating the treatment of BM in breast cancer patients, discuss presently available treatment options, and suggest potential directions of future therapeutic targets.

scholarly journals Radiofrequency ablation versus traditional liver resection and chemotherapy for liver metastases from gastric cancer

2020 ◽  
Vol 48 (7) ◽  
pp. 030006052094050
Author(s):  
Kezhong Tang ◽  
Bo Zhang ◽  
Linping Dong ◽  
Lantian Wang ◽  
Zhe Tang
Keyword(s):  
Gastric Cancer ◽  
Radiofrequency Ablation ◽  
Liver Resection ◽  
Liver Metastasis ◽  
Liver Metastases ◽  
Statistical Significance ◽  
Local Treatment ◽  
Long Term Outcomes ◽  
Short And Long Term

Objective To compare the short- and long-term outcomes of radiofrequency ablation (RFA) versus liver resection and chemotherapy for liver metastases from gastric cancer. Methods We retrospectively evaluated 50 patients who underwent curative gastrectomy and local treatments for liver metastases (RFA, n = 20; liver resection, n = 20; and chemotherapy, n = 10) from 2008 to 2018. Results The short- and long-term outcomes of each local treatment were evaluated. The median overall survival (OS) after RFA was similar to that after liver resection (20 vs. 20 months, respectively) and longer than that after chemotherapy (20 vs. 10 months, respectively). The 3-year OS and progression-free survival (PFS) rates after RFA were 20% and 10%, respectively, while those in the liver resection group were 23.5% and 23.5%, respectively. The 3-year OS rate after chemotherapy was 10%. The size and number of metastases were prognostic factors for patients with gastric cancer with liver metastasis without statistical significance. Conclusions Among patients with liver metastasis from gastric cancer, OS and PFS were satisfactory and comparable between RFA and liver resection but better than those of chemotherapy. RFA is an appropriate option for patients with gastric cancer who have a solitary liver metastasis measuring ≤3.0 cm.

scholarly journals Identification of Alternatively-Activated Pathways between Primary Breast Cancer and Liver Metastatic Cancer Using Microarray Data

Genes ◽  
2019 ◽  
Vol 10 (10) ◽  
pp. 753 ◽  
Author(s):  
Wang ◽  
Li ◽  
Liu ◽  
Kinnebrew ◽  
Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Liver Metastasis ◽  
Calcium Signaling ◽  
Microarray Data ◽  
Primary Breast Cancer ◽  
Cytokine Receptor ◽  
Receptor Interaction ◽  
Tgf Beta ◽  
Breast Cancer Liver Metastasis ◽  
Alternatively Activated

Alternatively-activated pathways have been observed in biological experiments in cancer studies, but the concept had not been fully explored in computational cancer system biology. Therefore, an alternatively-activated pathway identification method was proposed and applied to primary breast cancer and breast cancer liver metastasis research using microarray data. Interestingly, the results show that cytokine-cytokine receptor interaction and calcium signaling were significantly enriched under both conditions. TGF beta signaling was found to be the hub in network topology analysis. In total, three types of alternatively-activated pathways were recognized. In the cytokine-cytokine receptor interaction pathway, four active alteration patterns in gene pairs were noticed. Thirteen cytokine-cytokine receptor pairs with inverse activity changes of both genes were verified by the literature. The second type was that some sub-pathways were active under only one condition. For the third type, nodes were significantly active in both conditions, but with different active genes. In the calcium signaling and TGF beta signaling pathways, node E2F5 and E2F4 were significantly active in primary breast cancer and metastasis, respectively. Overall, our study demonstrated the first time using microarray data to identify alternatively-activated pathways in breast cancer liver metastasis. The results showed that the proposed method was valid and effective, which could be helpful for future research for understanding the mechanism of breast cancer metastasis.

scholarly journals Microwave ablation for breast cancer liver metastasis

HPB ◽  
2019 ◽  
Vol 21 ◽  
pp. S943
Author(s):  
E. Gringeri ◽  
R. Boetto ◽  
S.E. Pierobon ◽  
F.E. D'Amico ◽  
D. Bassi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Liver Metastasis ◽  
Microwave Ablation ◽  
Breast Cancer Liver Metastasis

scholarly journals Results of hepatic resection following breast cancer liver metastasis

HPB ◽  
2019 ◽  
Vol 21 ◽  
pp. S639
Author(s):  
K. Kobryń ◽  
E. Kobryń ◽  
K. Kobryń ◽  
M. Nowosad ◽  
W. Patkowski ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Liver Metastasis ◽  
Hepatic Resection ◽  
Breast Cancer Liver Metastasis

scholarly journals Percutaneous Ablation-Induced Immunomodulation in Hepatocellular Carcinoma

2020 ◽  
Vol 21 (12) ◽  
pp. 4398 ◽  
Author(s):  
Lucile Dumolard ◽  
Julien Ghelfi ◽  
Gael Roth ◽  
Thomas Decaens ◽  
Zuzana Macek Jilkova
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiofrequency Ablation ◽  
Thermal Ablation ◽  
Microwave Ablation ◽  
Treatment Options ◽  
Ablation Techniques ◽  
High Rate ◽  
Percutaneous Ablation ◽  
Ablative Therapies ◽  
Immune Changes

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related deaths worldwide and its incidence is rising. Percutaneous locoregional therapies, such as radiofrequency ablation and microwave ablation, are widely used as curative treatment options for patients with small HCC, but their effectiveness remains restricted because of the associated high rate of recurrence, occurring in about 70% of patients at five years. These thermal ablation techniques have the particularity to induce immunomodulation by destroying tumours, although this is not sufficient to raise an effective antitumour immune response. Ablative therapies combined with immunotherapies could act synergistically to enhance antitumour immunity. This review aims to understand the different immune changes triggered by radiofrequency ablation and microwave ablation as well as the interest in using immunotherapies in combination with thermal ablation techniques as a tool for complementary immunomodulation.

Sign in / Sign up

Export Citation Format

Share Document